Loading...

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer

Although early breast cancer (BC) is highly curable, advanced or metastatic disease poses numerous challenges in terms of medical management and treatment decisions and is associated with significantly worse prognosis. Among the new targeted agents, anticancer drugs exploiting the cell-cycle machine...

Full description

Saved in:
Bibliographic Details
Published in:Drug Des Devel Ther
Main Authors: Corona, Silvia Paola, Generali, Daniele
Format: Artigo
Language:Inglês
Published: Dove Medical Press 2018
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5818877/
https://ncbi.nlm.nih.gov/pubmed/29497278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137783
Tags: Add Tag
No Tags, Be the first to tag this record!